Research Multiple Sclerosis
The investigative use of cannabidiol in multiple sclerosis, as an alternative to THC or illegal cannabis.
Currently a licensed product called Sativex exists which contains both a psychoactive (THC) and non-psychoactive (CBD) component of cannabis plants.
This mixture is called Nabiximols.
Many patients report they cannot tolerate the licensed product due to side effects. The side effects are likely to be caused by the psychoactive component of Sativex.
This is equally also true of multiple sclerosis patients taking street cannabis they source for themselves.
Our aim is to capture data from patients who have switched from THC containing cannabis products, to non-THC cannabis products – and determine if the efficacy and symptom control are similar.